Literature DB >> 318212

Cefoxitin for treatment of infections due to anaerobic bacteria.

B D Kirby1, D F Busch, D M Citron, S M Finegold.   

Abstract

Twenty-seven patients with 29 infections due to anaerobic or mixed anaerobic-aerobic bacteria were treated with cefoxitin. From the 27 patients 99 isolates of anaerobic bacteria and 70 isolates of aerobic bacteria were recovered. Twelve pleuropulmonary infections, 12 soft tissue infections, three bone infections, and two intraabdominal infections were treated. Twenty-six of the 29 infections were completely or partially eradicated; the remaining three infections were unchanged. One-third of the patients experienced phlebitis; in two instances severe phlebitis caused discontinuation of therapy. In this study cefoxitin appeared to be an effective single agent for the therapy of infections due to specific anaerobic bacteria or to a mixed flora of anaerobic and aerobic bacteria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 318212     DOI: 10.1093/clinids/1.1.113

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

Review 1.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 2.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 3.  Susceptibility testing of anaerobic bacteria.

Authors:  S M Finegold
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

4.  Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.

Authors:  K E Aldridge; H M Wexler; C V Sanders; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 5.  Clinical relevance of antimicrobial susceptibility testing.

Authors:  S M Finegold
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.